Peritonitis caused by Agrobacterium tumefaciens in a child on peritoneal dialysis.

1. Macdougall IC. Once-weekly erythropoietic therapy: is there difference between the available preparations? Nephrol Dial Transplant 2002; 17: 2047–2051 2. Locatelli F, Olivares J, Walker R et al. on behalf of the European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60: 741–747 3. Nissenson R, Swan SK, Lindberg JS et al. Randomized controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 110–118 4. Vanrenterghem Y, Barany P, Mann JFE et al. on behalf of the European/Australian NESP 970200 Study Group. Randomized trial of Darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002; 62: 2167–2175 5. Horl W. IV darbepoetin alfa is more effective than IV rHu-Epo in maintaining target Hb concentrations in patients with renal anemia. J Am Soc Nephrol 2002; 17[Abstracts Suppl 1]: 24 6. Besarab A, Reynes CM, Homberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 439–446 7. Levin A. Preaching and practice: evidence-based medicine and the accountability of nephrologists within the health care system. The implications of the findings of the cost-saving potential of subcutaneous versus intravenous epoetin therapy. Am J Kidney Dis 2002; 40: 662–663